Kiromic BioPharma (KRBP) Stock Price, News & Analysis

Company Overview

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.21 to $1.66
• 52-Week Range: N/A
• Volume: 107,749 shs
• Average Volume: 11,347 shs
• Market Capitalization: $330 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KRBP Stock Analysis - Frequently Asked Questions

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its earnings results on Friday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter.

When did Kiromic BioPharma's stock split?

Kiromic BioPharma shares reverse split before market open on Monday, March 13th 2023.The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

What other stocks do shareholders of Kiromic BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiromic BioPharma investors own include Athenex (ATNX), KLX Energy Services (KLXE), Brainstorm Cell Therapeutics (BCLI), NGL Energy Partners (NGL), Orchard Therapeutics (ORTX), TherapeuticsMD (TXMD) and Achilles Therapeutics (ACHL).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 8/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRBP
• CIK: 1792581
• Web: www.kiromic.com
• Phone: 832-968-4888
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -277.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.29) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 1,217,000
• Market Cap: $330 thousand
• Optionable: Not Optionable
• Beta: 1.66